China SXT Pharmaceuticals, Inc. announced that it has entered into certain securities purchase agreement for 1,625,798 ordinary shares at a per share purchase price of $1.35 for total gross proceeds of $2,194,827 on September 22, 2022. The transaction included participation from individual investor Zhijun Xiao for 1,625,798 Ordinary Shares at a per share purchase price of $1.35 for the gross proceeds of $2,194,827.3. The ordinary shares will be issued to the Investor upon satisfaction of all closing conditions, including the Nasdaq's completion of its review of the notification to Nasdaq regarding the listing of the shares. The shares to be issued in the transaction are exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Regulation S promulgated thereunder.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | -0.95% | -4.59% | -73.80% |
1st Jan change | Capi. | |
---|---|---|
-73.80% | 757K | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- SXTC Stock
- News China SXT Pharmaceuticals, Inc.
- China SXT Pharmaceuticals, Inc. announced that it has received $2.194827 million in funding